|
|
Post by kbrion77 on Sept 12, 2016 7:53:40 GMT -5
fortune.com/2016/09/12/sanofi-alphabet-joint-venture-diabetes/“The company will leverage Verily’s (formerly Google Life Sciences) experience in miniaturized electronics, analytics, and consumer software development, and Sanofi’s clinical expertise and experience in bringing innovative treatments to people living with diabetes,” the two companies said on Monday.The JV, called Onduo, “will initially focus on the type 2 diabetes community, specifically on developing solutions that could help people make better decisions about their day to day health, ranging from improved medication management to improved habits and goals,” Sanofi and Verily said.
A spokeswoman for Sanofi said products on sale would include connected objects such as insulin pens and online services.So basically what I take from this is either the entire Pharma industry has no interest in inhaled insulin and believes it is a total waste or Sanofi had absolutely no interest in cannibalizing their current diabetes model. What is more innovative than inhaled insulin? So their whole innovation is an insulin pen you can connect to the cloud, huh? I guess we will find out the future of Afrezza in the next few months but give me a break with Alphabet/Sanofi speaking about innovation.
|
|
|
|
Post by peppy on Sept 12, 2016 8:03:51 GMT -5
fortune.com/2016/09/12/sanofi-alphabet-joint-venture-diabetes/“The company will leverage Verily’s (formerly Google Life Sciences) experience in miniaturized electronics, analytics, and consumer software development, and Sanofi’s clinical expertise and experience in bringing innovative treatments to people living with diabetes,” the two companies said on Monday.The JV, called Onduo, “will initially focus on the type 2 diabetes community, specifically on developing solutions that could help people make better decisions about their day to day health, ranging from improved medication management to improved habits and goals,” Sanofi and Verily said.
A spokeswoman for Sanofi said products on sale would include connected objects such as insulin pens and online services.So basically what I take from this is either the entire Pharma industry has no interest in inhaled insulin and believes it is a total waste or Sanofi had absolutely no interest in cannibalizing their current diabetes model. What is more innovative than inhaled insulin? So their whole innovation is an insulin pen you can connect to the cloud, huh? I guess we will find out the future of Afrezza in the next few months but give me a break with Alphabet/Sanofi speaking about innovation. Is that what it said? I read a promotional piece trying to link Sanofi to Google. Google is doing miniature electronics. Quote: Sanofi’s clinical expertise and experience in bringing innovative treatments to people living with diabetes,” the two companies said on Monday.
reply: That is where the writer lost me.
Google makes/wants the miniature electronics and data. Sanofi wants?
|
|
|
|
Post by kbrion77 on Sept 12, 2016 8:20:54 GMT -5
mediaroom.sanofi.com/sanofi-and-verily-life-sciences-announce-launch-of-onduo-a-joint-venture-to-develop-comprehensive-diabetes-management-platform/From Sanofi's website. As if it didn't get anymore weird see the quote below: “With Onduo, Sanofi and Verily are bringing forward a platform that is novel and critical in diabetes management,” said, Steven V. Edelman, M.D., Founder and Director, TCOYD. “Onduo is a company focused on the improvement of health outcomes through the marriage of technology and medicine. Its information-based solutions align well with TCOYD’s mission to empower people with diabetes and their loved ones to effectively and easily take control of diabetes. We welcome and support Onduo’s efforts and look forward to their progress.” Is this not our Afrezza advocate Steven Edelman?  Not saying he needs to pick sides but he has definitely advocated about his patients receiving less shots on a weekly basis from using Afrezza. Just bizarre IMO.
|
|
|
|
Post by agedhippie on Sept 12, 2016 9:10:50 GMT -5
This is all about connected devices and not drugs. Sanofi is proposing pens that talk to your phone and track your usage. Hook that up with the Dexcom/Google sensor, collect all the data and crunch the numbers. Out pops personalized guidance.
The IoT area is really hot in the medical world at the moment. Everyone is salivating over all that data.
|
|
|
|
Post by lakon on Sept 12, 2016 10:20:01 GMT -5
This is all about connected devices and not drugs. Sanofi is proposing pens that talk to your phone and track your usage. Hook that up with the Dexcom/Google sensor, collect all the data and crunch the numbers. Out pops personalized guidance. The IoT area is really hot in the medical world at the moment. Everyone is salivating over all that data. A cynic might say that IoT is really hot right now, and everyone is salivating over all that cash sloshing around... |
|
|
|
Post by agedhippie on Sept 12, 2016 12:12:44 GMT -5
This is all about connected devices and not drugs. Sanofi is proposing pens that talk to your phone and track your usage. Hook that up with the Dexcom/Google sensor, collect all the data and crunch the numbers. Out pops personalized guidance. The IoT area is really hot in the medical world at the moment. Everyone is salivating over all that data. A cynic might say that IoT is really hot right now, and everyone is salivating over all that cash sloshing around... It would be hard to disagree with that. A lot of people are busily rebadging their existing wireless solutions that have been out there for years as IoT and looking around eagerly for money. |
|
|
|
Post by uvula on Sept 12, 2016 14:05:03 GMT -5
The joint venture is worth $500M. They could have bought mnkd for less than that.
|
|
|
|
Post by mannmade on Sept 12, 2016 14:44:07 GMT -5
If MannKind wanted to sell at 1.25 a share...
|
|
|
|
Post by mannmade on Sept 12, 2016 18:58:30 GMT -5
Alphabet and Sanofi in $500 million diabetes joint venture
REUTERS SEPTEMBER 12, 2016 1:54 AM
TAGS: ALPHABET, ALPHABET-INC, FUNDING DAILY, GOOGLE, SANOFI, VERILY
A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014.
Above: A logo is seen in front of the entrance at the headquarters French drugmaker Sanofi in Paris October 30, 2014.
Image Credit: REUTERS/Christian Hartmann/File Photo
PARIS (Reuters) — French drugmaker Sanofi and Google owner Alphabet’s life sciences firm Verily are to invest about $500 million in a diabetes joint venture combining devices with services, an example of growing ties between the pharma and tech sectors.
Sanofi, which made the announcement on Monday, said last year it was working on a partnership with Google in diabetes.
“The company will leverage Verily’s experience in miniaturized electronics, analytics, and consumer software development, with Sanofi’s clinical expertise and experience in bringing innovative treatments to people living with diabetes,” the two companies said in a statement on Monday.
The Sanofi deal comes just after a month after British drugmaker GlaxoSmithKline and U.S.-based Verily – formerly Google Life Sciences – created a new company focused on fighting diseases by targeting electrical signals in the body, jump-starting a novel field of medicine called bioelectronics.
Nearly 400 million people worldwide have diabetes, with the type 2 version accounting for more than 90 percent of cases. Without proper treatment or lifestyle changes, those numbers are expected to grow substantially in the coming years.
The JV, called Onduo, “will initially focus on the type 2 diabetes community, specifically on developing solutions that could help people make better decisions about their day-to-day health, ranging from improved medication management to improved habits and goals,” Sanofi and Verily said.
A spokeswoman for Sanofi said products on sale would include connected objects such as insulin pens and online services.
She said Sanofi had invested $248 million in the joint venture, in which the French group controls a 50 percent stake.
The French group is working hard to revive declining sales in its diabetes division, hurt by sustained pricing pressure in the United States, the world’s largest health market.
(Reporting by Matthias Blamont and Andrew Callus; Editing by Greg Mahlich and Geert De Clercq)
|
|
|
|
Post by avichen on Sept 12, 2016 19:45:21 GMT -5
Ok... I'll remove my Chrome, switch to firefox, get the new Apple phone...  , switch to use bing for search. |
|
|
|
Post by otherottawaguy on Sept 13, 2016 7:24:31 GMT -5
Don't get so worked up about this deal.Sanofi will probably not realize that they are working with a leading edge solution and partner.
My guess is they will not even give it a half assed effort and will terminate the parnership within 12 to 18 months based upon previous track records...
OOG
|
|
Not saying he needs to pick sides but he has definitely advocated about his patients receiving less shots on a weekly basis from using Afrezza. Just bizarre IMO.
, switch to use bing for search.